Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
NCT01862926
Completed
Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many other connective tissue diseases (CTDs) such as polymyositis/dermatomyositis and mixed connective tissue disease. When ILD is extensive and/or progressive, immunosuppressive medication is often required to stabilize lung disease and alleviate symptoms. Current standard care... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/06/2021
Locations: Royal Brompton Hospital, London, Not set
Conditions: Interstitial Lung Disease, Scleroderma, Idiopathic Inflammatory Myositis, Mixed Connective Tissue Disease
Register for Updates
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
NCT02724163
Recruiting
The main purpose of this study is : 1. To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or liposomal daunorubicin in induction 2. To compare mitoxantrone (anthracenedione) \& cytarabine with liposomal daunorubicin (anthracycline) \& cytarabine as induction therapy. (Randomisation 1 (R1) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
09/30/2021
Locations: Women and Children's Hospital Adelaide, Adelaide, Not set +67 locations
Conditions: Acute Myeloid Leukaemia
Register for Updates
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
NCT02566993
Completed
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/29/2021
Locations: Alabama Oncology, Birmingham, Alabama +159 locations
Conditions: Small-cell Lung Cancer
Register for Updates
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
NCT02132949
Completed
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant treatment in participants with HER2-positive locally advanced, inflammatory, or early-stage breast cancer. Each investigator will choose a treatment regimen (A or B) for all of their participants to follow. Treatment regimen A (for Cohort A) will include dose-dense doxoru... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2021
Locations: University of South Alabama; Mitchell Cancer Institute, Mobile, Alabama +79 locations
Conditions: Breast Cancer
Register for Updates
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
NCT02761915
Completed
The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART therapy in patients with relapsed or refractory neuroblastoma. 1RG-CART therapy is a novel immunotherapy under investigation in which patients have their T-cells (a type of white blood cell) collected and modified in the laboratory, before they are given back to the patient. The T-cells are modified to express a chimeric antigen receptor (CAR) which targets disialoganglioside (GD2), a marker expressed... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
07/23/2021
Locations: University College London Institute of Child Health & Great Ormond Street Hospital, London, Not set
Conditions: Relapsed or Refractory Neuroblastoma
Register for Updates
Randomised Trial in Waldenstrom's Macroglobulinaemia
NCT01592981
Completed
The purpose of this trial is to assess tolerability and efficacy of the Bortezomib, Cyclophosphamide and Rituximab combination as initial therapy for previously untreated patients with symptomatic Waldenstrom's macroglobulinaemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2021
Locations: Basingstoke & North Hampshire Hospital, Basingstoke, Not set +29 locations
Conditions: Waldenstrom's Macroglobulinaemia
Register for Updates
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
NCT00290667
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with comb... Read More
Gender:
ALL
Ages:
Between 61 years and 80 years
Trial Updated:
05/14/2021
Locations: University Hospital Brno, Brno, Not set +337 locations
Conditions: Lymphoma
Register for Updates
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
NCT01220128
Terminated
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2021
Locations: GSK Investigational Site, Newark, Delaware +35 locations
Conditions: Neoplasms, Breast
Register for Updates
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
NCT01516567
Unknown
Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
03/17/2021
Locations: University Hospitals Leuven, Leuven, Not set +8 locations
Conditions: Primary Mediastinal Large B Cell Lymphoma
Register for Updates
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00004179
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether chemotherapy is more effective with or without rituximab for relapsed non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying combination chemotherapy and rituximab to s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/11/2021
Locations: Canberra Hospital, Garran, Australian Capital Territory +260 locations
Conditions: Lymphoma
Register for Updates
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
NCT02032277
Completed
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/15/2021
Locations: Scottsdale Healthcare /ID# 120473, Scottsdale, Arizona +157 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)
NCT04389229
Withdrawn
An open label, multi-centre Phase 1/2a study of modified and unmodified autologous Tumour Infiltrating Lymphocytes (TIL) in patients with platinum-resistant ovarian cancer. The purpose of this phase I/II study is to evaluate the feasibility and safety of both standard unmodified TIL (UTIL-01) and TIL engineered to express the co-stimulatory receptor CoStAR (CoTIL-01) in platinum resistant ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/11/2020
Locations: Queens Elizabeth Hospital, Birmingham, Not set +1 locations
Conditions: Ovarian Cancer Metastatic
Register for Updates